Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progress towards the UNAIDS 90-90-90 targets among persons aged 50 and older living with HIV in 13 African countries.
Farley SM, Wang C, Bray RM, Low AJ, Delgado S, Hoos D, Kakishozi AN, Harris TG, Nyirenda R, Wadonda N, Li M, Amuri M, Juma J, Kancheya N, Pietersen I, Mutenda N, Natanael S, Aoko A, Ngugi EW, Asiimwe F, Lecher S, Ward J, Chikwanda P, Mugurungi O, Moyo B, Nkurunziza P, Aibo D, Kabala A, Biraro S, Ndagije F, Musuka G, Ndongmo C, Shang J, Dokubo EK, Dimite LE, McCullough-Sanden R, Bissek AC, Getaneh Y, Eshetu F, Nkumbula T, Tenthani L, Kayigamba FR, Kirungi W, Musinguzi J, Balachandra S, Kayirangwa E, Ayite A, West CA, Bodika S, Sleeman K, Patel HK, Brown K, Voetsch AC, El-Sadr WM, Justman JJ. Farley SM, et al. Among authors: nkurunziza p. J Int AIDS Soc. 2022 Sep;25 Suppl 4(Suppl 4):e26005. doi: 10.1002/jia2.26005. J Int AIDS Soc. 2022. PMID: 36176030 Free PMC article.
Coronavirus Disease 2019 (COVID-19) Mitigation Efforts and Testing During an In-Person Training Event-Uganda, 12-29 October 2020.
Laws RL, Biraro S, Kirungi W, Gianetti B, Aibo D, Awor AC, West C, Sachathep KK, Kiyingi H, Ward J, Mwangi C, Nkurunziza P, Okimait D, Currie D, Ajiboye A, Moore CS, Patel H, Sendagala S, Naluguza M, Mugisha V, Low A, Delgado S, Hoos D, Brown K, Galbraith JS, Hladik W, Nelson L, El-Sadr W, Musinguzi J, Voetsch AC. Laws RL, et al. Among authors: nkurunziza p. Clin Infect Dis. 2021 Jul 15;73(Suppl 1):S42-S44. doi: 10.1093/cid/ciab331. Clin Infect Dis. 2021. PMID: 33912911 Free PMC article.
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group. Dolling DI, et al. Among authors: nkurunziza p. BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3. BMC Infect Dis. 2017. PMID: 28222702 Free PMC article.
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Goodall RL, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, Kityo C, Gilks C, Kaleebu P, Pillay D, Gupta RK; DART Virology Group. Goodall RL, et al. Among authors: nkurunziza p. J Antimicrob Chemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583. J Antimicrob Chemother. 2017. PMID: 28160504 Free PMC article.
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugyenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team. Gilks CF, et al. PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437399 Free PMC article. Clinical Trial.
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndembi N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Teams. Goodall RL, et al. Among authors: nkurunziza p. J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14. J Antimicrob Chemother. 2014. PMID: 24633208 Free PMC article. Clinical Trial.
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK; DART Virology Group; DART Trial Team. Sutherland KA, et al. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10. AIDS Res Hum Retroviruses. 2015. PMID: 26258548 Free PMC article.
20 results